Castle Biosciences Management
Management criteria checks 3/4
Castle Biosciences' CEO is Derek Maetzold, appointed in Sep 2007, has a tenure of 18.92 years. total yearly compensation is $6.79M, comprised of 11.1% salary and 88.9% bonuses, including company stock and options. directly owns 0.76% of the company’s shares, worth $7.05M. The average tenure of the management team and the board of directors is 5.1 years and 5.8 years respectively.
Key information
Derek Maetzold
Chief executive officer
US$6.8m
Total compensation
| CEO salary percentage | 11.07% |
| CEO tenure | 18.9yrs |
| CEO ownership | 0.8% |
| Management average tenure | 5.1yrs |
| Board average tenure | 5.8yrs |
Recent management updates
Recent updates
Narrative Update • Aug 02
CSTL: Strong Test Demand And Guidance Raise Confidence In Future Profitability
Analysts have raised their price target on Castle Biosciences stock from $52 to $57, citing stronger revenue trends, higher guidance and increased confidence in the company’s long-term profitability potential. Analyst Commentary Bullish analysts have been highlighting several supportive factors for Castle Biosciences, centering on revenue trends, guidance, and the company’s path toward sustained profitability.
Narrative Update • Jul 09
CSTL: Raised Fair Value Highlights Future Potential Of Quality Revenue Mix
Analysts have raised the fair value estimate for Castle Biosciences stock by $5 to $35, citing Street research that highlights quality revenue growth potential, solid gross margins, and a path toward sustainable profitability as key supports for higher price targets. Analyst Commentary Recent Street research on Castle Biosciences reflects a mix of optimism about the company’s revenue outlook and profitability path, alongside more cautious adjustments to price targets that highlight execution and valuation risks.
Narrative Update • Jun 25
CSTL: Test Volume Execution And Profit Path Will Underpin Upside Potential
Analysts have updated their price outlook on Castle Biosciences to reflect a $44.0 target, with the shift framed by recent Street research that highlights both reduced targets from some firms in the $35 to $40 range and continued emphasis on revenue growth potential, profit prospects and a solid balance sheet. Analyst Commentary Recent Street research on Castle Biosciences presents a mix of optimism around growth and profitability alongside more cautious revisions to price targets, giving you a fuller picture of how expectations are being reset.Narrative Update • Jun 08
CSTL: Test Volume Execution And 2026 Guidance Will Underpin Upside Potential
Analysts have trimmed the price target on Castle Biosciences to $44.00 from $45.88, reflecting recent target reductions from multiple firms, even as they point to what they describe as solid test volume trends and ongoing upside potential in the stock. Analyst Commentary Recent Street commentary on Castle Biosciences points to a mixed setup, with target cuts clustered in the mid US$30s to low US$40s range and a focus on how execution in core tests might support that valuation.Narrative Update • May 24
CSTL: 2026 Clinical Data And Guidance Will Support Upside Potential
Narrative Update: Castle Biosciences The updated analyst price target for Castle Biosciences shifts from $47.25 to $45.88 as analysts factor in the recent cuts in Street targets, along with views that solid Q1 volume growth in TissueCypher and DecisionDx-Melanoma still supports potential upside over time. Analyst Commentary Recent Street research on Castle Biosciences highlights a mix of optimism around execution and caution reflected in lower price targets.Narrative Update • Apr 22
CSTL: 2026 Clinical Data And Guidance Will Support Higher Confidence
Analysts have trimmed their modeled fair value for Castle Biosciences to $47.25 from $48.50 as they recalibrate long term revenue growth, profit margin, and future P/E assumptions following a mix of recent price target increases and a reduction from different research firms. Analyst Commentary Bullish Takeaways Bullish analysts who raised their price targets highlight room for upside in their models, which typically reflects confidence in the company’s ability to execute on its current pipeline and commercial plans.Narrative Update • Apr 04
CSTL: Preliminary 2025 Update Will Support Higher Confidence In 2026 Revenue
Analysts have lifted their price targets on Castle Biosciences by up to $17, reflecting updated models that now reference 2026 revenue estimates and recent preliminary 2025 revenue disclosures. Analyst Commentary Recent price target changes cluster around updated 2026 revenue frameworks and the company’s preliminary 2025 revenue disclosure.Seeking Alpha • Mar 30
Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside
Summary Castle Biosciences, Inc. is positioned as a leader in precision cancer diagnostics, notably with DecisionDx-Melanoma, offering scalable, clinically validated solutions. CSTL reported strong Q4/FY2025 revenue growth and robust cash reserves but faces a projected EPS decline in 2026 as it invests aggressively in growth and commercialization. DecisionDx-Melanoma stands out as a de-risked, durable growth driver with high clinical utility, workflow integration, and payer support, targeting a large and growing melanoma market. I assign CSTL a conviction rating of 3/5, initiating a pilot position near technical support, with plans to build exposure as the market digests 2026 earnings and product adoption. Read the full article on Seeking AlphaNarrative Update • Mar 20
CSTL: Preliminary 2025 Revenue Signals Stronger Confidence In 2026 Outlook
Analysts have lifted their price targets on Castle Biosciences by amounts ranging up to $17, pointing to updated revenue estimates through 2026 and recent preliminary 2025 revenue disclosures as key drivers of their revised outlooks. Analyst Commentary Recent research notes focus on how preliminary 2025 revenue disclosures and updated 2026 revenue estimates feed into Castle Biosciences' valuation, with several firms adjusting their price targets to reflect these updated assumptions.Narrative Update • Mar 06
CSTL: Preliminary 2025 Revenue Outlook Will Support Higher 2026 Expectations
Analysts have modestly adjusted their fair value estimate for Castle Biosciences to $48.50, citing updated revenue growth and profit margin assumptions, as well as a slightly lower future P/E multiple, as reflected in recent price target increases from several firms. Analyst Commentary Recent research updates on Castle Biosciences have centered on revised revenue assumptions for 2025 and beyond, along with higher price targets that feed into the updated fair value estimate of $48.50.Narrative Update • Feb 20
CSTL: Preliminary 2025 Revenue Outlook Will Support Higher 2026 Expectations
Analysts have raised their average price target on Castle Biosciences by $14, citing updated models that now rely more on 2026 revenue estimates and recent preliminary 2025 revenue disclosures. Analyst Commentary Recent research updates on Castle Biosciences focus heavily on how preliminary 2025 revenue information feeds into 2026 models, which in turn support higher price targets.Narrative Update • Feb 05
CSTL: Preliminary 2025 Revenue Signals Will Support Extended 2026 Upside Potential
Narrative Update The updated analyst price target for Castle Biosciences moves from $46.00 to about $48.57. Analysts point to refreshed assumptions around fair value, discount rate, revenue growth, profit margin and future P/E as the key drivers behind the change.Narrative Update • Jan 21
CSTL: Extended 2026 Revenue View And Test Adoption Will Support Upside
Narrative Update: Castle Biosciences Analysts have lifted their fair value estimate for Castle Biosciences from US$42.50 to US$46.00, citing updated modeling that now anchors price targets on 2026 revenue expectations following preliminary 2025 revenue disclosures. Analyst Commentary Recent Street commentary around Castle Biosciences is centering on how the preliminary 2025 revenue update reshapes expectations and valuation anchors out to 2026.Narrative Update • Jan 06
CSTL: Dermatology Test Adoption And New Launches Will Support Balanced Outlook
Analysts have lifted their price target on Castle Biosciences from US$38.75 to US$42.50, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News New data from a prospective multicenter study comparing NGS-based mutation analysis with the combination of DecisionDx-UM and PRAME for uveal melanoma outcomes was published in Nature Communications, with DecisionDx-UM described as widely adopted in the U.S. standard of care and included in AJCC and NCCN guidelines (Key Developments).Narrative Update • Dec 13
CSTL: Broader Dermatology Test Adoption Will Support Balanced Long-Term Outlook
Analysts have raised their price target on Castle Biosciences to approximately 38.75 dollars from about 35.63 dollars, citing stronger expectations for revenue growth and slightly improved profit margins, despite a modestly higher discount rate and lower projected future P E multiple. What's in the News An independent expert consensus panel endorsed Castle Biosciences DecisionDx-Melanoma test as providing robust, clinically validated prognostic information that improves melanoma risk stratification and supports more precise treatment decisions (expert consensus paper).Analysis Article • Nov 06
Castle Biosciences, Inc.'s (NASDAQ:CSTL) 44% Share Price Surge Not Quite Adding Up
Despite an already strong run, Castle Biosciences, Inc. ( NASDAQ:CSTL ) shares have been powering on, with a gain of...Analysis Article • Aug 24
What Castle Biosciences, Inc.'s (NASDAQ:CSTL) 30% Share Price Gain Is Not Telling You
The Castle Biosciences, Inc. ( NASDAQ:CSTL ) share price has done very well over the last month, posting an excellent...Analysis Article • Jun 28
Is Castle Biosciences (NASDAQ:CSTL) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • May 23
Some Confidence Is Lacking In Castle Biosciences, Inc. (NASDAQ:CSTL) As Shares Slide 28%
Unfortunately for some shareholders, the Castle Biosciences, Inc. ( NASDAQ:CSTL ) share price has dived 28% in the last...Analysis Article • Apr 16
When Should You Buy Castle Biosciences, Inc. (NASDAQ:CSTL)?
While Castle Biosciences, Inc. ( NASDAQ:CSTL ) might not have the largest market cap around , it saw a double-digit...Seeking Alpha • Apr 14
Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern
Summary Castle Biosciences offers diverse diagnostic tests, with DecisionDx-Melanoma being a key revenue driver, but faces potential Medicare reimbursement loss for DecisionDx-SCC in 2025. The company is expanding its portfolio with TissueCypher and IDgenetix, showing strong growth, though IDgenetix faces uncertain long-term performance. Castle is well capitalized with $293 million in cash, providing a strong runway, but continues to burn cash, mainly on general and admin expenses. Trading near 52-week lows, CSTL stock presents a good entry point, but investors should watch for clarity on the SCC non-coverage issue. Read the full article on Seeking AlphaAnalysis Article • Feb 25
Pinning Down Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is Difficult Right Now
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...
New Narrative • Feb 13
Positive Clinical Adoption Of DecisionDx Tests Will Strengthen Future Market Position
Strong revenue growth driven by increased adoption of DecisionDx tests and promising market expansion suggests potential for significant future earnings.Analysis Article • Dec 12
Castle Biosciences (NASDAQ:CSTL) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Oct 15
Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?
Key Insights The projected fair value for Castle Biosciences is US$66.66 based on 2 Stage Free Cash Flow to Equity...Seeking Alpha • Aug 16
Castle Biosciences: Inflection Into Profitability
Summary Castle Biosciences is a fast-growing molecular diagnostics company with a focus on prognostic tests for cancer and mental health patients. The company inflected into net income and operating profitability in Q2 2024, driving institutional and retail interest. Castle Biosciences faces risks from the loss of its DecisionDX-SCC business and general obsolescence in the cancer prognostic testing field. Read the full article on Seeking AlphaAnalysis Article • Aug 11
Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts
Celebrations may be in order for Castle Biosciences, Inc. ( NASDAQ:CSTL ) shareholders, with the analysts delivering a...Analysis Article • Aug 08
Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Shareholders of Castle Biosciences, Inc. ( NASDAQ:CSTL ) will be pleased this week, given that the stock price is up...Analysis Article • Aug 04
Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up
Castle Biosciences, Inc. ( NASDAQ:CSTL ) shareholders are no doubt pleased to see that the share price has bounced 28...Analysis Article • Jul 12
Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Apr 30
Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$19m |
| Mar 31 2026 | n/a | n/a | -US$13m |
| Dec 31 2025 | US$7m | US$751k | -US$24m |
| Sep 30 2025 | n/a | n/a | -US$12m |
| Jun 30 2025 | n/a | n/a | -US$9m |
| Mar 31 2025 | n/a | n/a | -US$5m |
| Dec 31 2024 | US$7m | US$716k | US$18m |
| Sep 30 2024 | n/a | n/a | US$6m |
| Jun 30 2024 | n/a | n/a | -US$3m |
| Mar 31 2024 | n/a | n/a | -US$31m |
| Dec 31 2023 | US$2m | US$686k | -US$57m |
| Sep 30 2023 | n/a | n/a | -US$76m |
| Jun 30 2023 | n/a | n/a | -US$89m |
| Mar 31 2023 | n/a | n/a | -US$72m |
| Dec 31 2022 | US$8m | US$660k | -US$67m |
| Sep 30 2022 | n/a | n/a | -US$53m |
| Jun 30 2022 | n/a | n/a | -US$44m |
| Mar 31 2022 | n/a | n/a | -US$52m |
| Dec 31 2021 | US$7m | US$625k | -US$31m |
| Sep 30 2021 | n/a | n/a | -US$30m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$5m | US$550k | -US$10m |
| Sep 30 2020 | n/a | n/a | -US$3m |
| Jun 30 2020 | n/a | n/a | US$7m |
| Mar 31 2020 | n/a | n/a | US$6m |
| Dec 31 2019 | US$4m | US$770k | US$3m |
Compensation vs Market: Derek's total compensation ($USD6.79M) is above average for companies of similar size in the US market ($USD3.59M).
Compensation vs Earnings: Derek's compensation has been consistent with company performance over the past year.
CEO
Derek Maetzold (64 yo)
18.9yrs
Tenure
US$6,786,771
Compensation
Mr. Derek J. Maetzold founded Castle Biosciences Incorporated in September 2007 and serves as its President, Chief Executive Officer and Director since September 2007. He serves as the Director at AltheaDx...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 18.9yrs | US$6.79m | 0.76% $ 7.1m | |
| CFO & Treasurer | 8.7yrs | US$2.42m | 0.20% $ 1.8m | |
| Chief Operating Officer | 6yrs | US$2.36m | 0.36% $ 3.4m | |
| Chief Commercial Officer | 6yrs | US$2.36m | 0.26% $ 2.4m | |
| Vice President of Investor Relations & Corporate Affairs | no data | no data | no data | |
| Vice President of Sales | 4.2yrs | no data | no data | |
| VP of Marketing & Brand Manager of Uveal Melanoma (UM) | 1.9yrs | no data | no data | |
| Vice President of Human Resources | 6.1yrs | no data | no data | |
| Senior Vice President of Medical | 3.3yrs | no data | no data | |
| Senior VP of Clinical Services & Manufacturing Operations | less than a year | no data | no data | |
| Chief of Staff | less than a year | no data | no data |
5.1yrs
Average Tenure
60.5yo
Average Age
Experienced Management: CSTL's management team is seasoned and experienced (5.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 18.9yrs | US$6.79m | 0.76% $ 7.1m | |
| Independent Chairman of the Board | 13.9yrs | US$314.23k | 0.12% $ 1.1m | |
| Independent Director | 7.7yrs | US$293.69k | 0.11% $ 1.0m | |
| Independent Director | 5.3yrs | US$286.19k | 0.13% $ 1.2m | |
| Independent Director | 2.4yrs | US$317.28k | 0.11% $ 1.0m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.1yrs | US$281.19k | 0.12% $ 1.1m | |
| Independent Director | 6.3yrs | US$283.59k | 0.12% $ 1.1m | |
| Independent Director | 5.1yrs | US$286.28k | 0.13% $ 1.2m |
5.8yrs
Average Tenure
64.5yo
Average Age
Experienced Board: CSTL's board of directors are considered experienced (5.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/07 23:18 |
| End of Day Share Price | 2026/08/07 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Castle Biosciences, Inc. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Bamberger | Baird |
| Catherine Ramsey Schulte | Baird |
| Mark Massaro | BTIG |